Hence, the combination scheme with WEE1/PLK1 dual inhibitors may potentially optimize PARP inhibitor’s effect against GC and extend PARP inhibitor’s accessibility from HR-defective to a larger range of HR-proficient patients, which will be helpful for future clinical settings on cancer targeted therapy. This evidence concerns the gene PARP1 and cancer.